This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Look at lenacapavir as a capsid inhibitor for HIV
Ticker(s): GILDWho's the expert?
Institution: Montgomery Infectious Disease Associates
- Infectious Disease Physician at Montgomery Infectious Disease Associates
- Areas of expertise include HIV, Lyme disease and Nosocomial infections
- Familiar with VAX-31 phase 1/2 data
Interview Goaldiscussing the potential of Sunlenca (lencapavir) and the current landscape of HIV-1 treatments
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
